Table 1.
Overview of overall synthesis data (excluding synthesis for the purpose of condition testing and fail synthesis), as well as synthesis data for the respective pre-clinical and clinical study.
| [11C]mHED | Starting Activity [GBq] | Yield [GBq] | Yield [%EOB] | Molar Activity [GBq/µmol mHED] | Precursor Concentration [µg/mL] | mHED Concentration [µg/mL] |
|---|---|---|---|---|---|---|
| All synthesis (n = 32) | 114 ± 15 | 3 ± 2 | 2.5 ± 1.5 | 126 ± 97 | 8 ± 7 | 3 ± 8 |
| Patients: | ||||||
| Morbus Fabry (n = 5) | 124 ± 2 | 3.5 ± 0.4 | 2.9 ± 0.3 | 155 ± 85 | 6 ± 4 | 2 ± 1 |
| HTX (n = 9) | 120 ± 2 | 2.3 ± 1.3 | 2 ± 1 | 129 ± 148 | 5.5 ± 3.8 | 1.7 ± 2.8 |
| Animals (n = 11) | 122 ± 3 | 3 ± 2 | 2.4 ± 1.9 | 211 ± 152 | 4.6 ± 4.7 | 9 ± 19 |